Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
PurposeThe aim of this study was to develop a pragmatic nomogram for prediction of progressionfreesurvival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor(TKI) in EGFR mutant non-small cell lung cancer (NSCLC). Materials and MethodsA total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who receivedEGFR TKIs, were enrolled in this study. We developed the nomogram, using a Coxproportional hazard regression model for PFS. ResultsThe median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. MultivariateCox model identified disease status, performance status, chemotherapy line, response toEGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram forPFS was developed, based on these covariates. The concordance index for a nomogramwas 0.708, and the calibration was also good. ConclusionWe developed a nomogram, based on clinical characteristics, for prediction of the PFS toEGFR TKI in NSCLC patients with EGFR mutation.
Abstract
PurposeThe aim of this study was to develop a pragmatic nomogram for prediction of progressionfreesurvival (PFS) for the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor(TKI) in EGFR mutant non-small cell lung cancer (NSCLC). Materials and MethodsA total of 306 recurred or metastatic NSCLC patients with EGFR mutation, who receivedEGFR TKIs, were enrolled in this study. We developed the nomogram, using a Coxproportional hazard regression model for PFS. ResultsThe median PFS was 11.2 months. Response rate to EGFR TKI was 71.9%. MultivariateCox model identified disease status, performance status, chemotherapy line, response toEGFR TKI, and bone metastasis as independent prognostic factors, and the nomogram forPFS was developed, based on these covariates. The concordance index for a nomogramwas 0.708, and the calibration was also good. ConclusionWe developed a nomogram, based on clinical characteristics, for prediction of the PFS toEGFR TKI in NSCLC patients with EGFR mutation.
참고문헌 (25)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Han SW, "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 23, pp.2493~2501 (2005)
- Takano T, "Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer", J Clin Oncol, 23, pp.6829~6837 (2005)
- Mitsudomi T, "Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence", J Clin Oncol, 23, pp.2513~2520 (2005)
- Keedy VL, "American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy", J Clin Oncol, 29, pp.2121~2127 (2011)
- Azzoli CG, "American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer", J Clin Oncol, 27, pp.6251~6266 (2009)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Keam B, "Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer", Int J Clin Oncol (2013)[DOI]
- Kim YT, "Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung", Lung Cancer, 59, pp.111~118 (2008)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", J Natl Cancer Inst, 92, pp.205~216 (2000), European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
- Keam B, "Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy", J Cancer Res Clin Oncol, 137, pp.1301~1308 (2011)
- Iasonos A, "How to build and interpret a nomogram for cancer prognosis", J Clin Oncol, 26, pp.1364~1370 (2008)
- Harrell FE Jr, "Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors", Stat Med, 15, pp.361~387 (1996)
- Hanley JA, "The meaning and use of the area under a receiver operating characteristic (ROC) curve", Radiology, 143, pp.29~36 (1982)
- Nam BH, "Discrimination and calibration in survival analysis" (2000), Boston University
- Pencina MJ, "Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation", Stat Med, 23, pp.2109~2123 (2004)
- Heagerty PJ, "Time-dependent ROC curves for censored survival data and a diagnostic marker", Biometrics, 56, pp.337~344 (2000)
- Florescu M, "National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21", J Thorac Oncol, 3, pp.590~598 (2008)
- Kim ST, "Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment", Oncology, 79, pp.78~84 (2010)
- Chung KP, "Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment", Chest, 141, pp.420~428 (2012)
- Nose N, "Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung", Lung Cancer, 71, pp.350~355 (2011)
- Ludovini V, "Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer", J Thorac Oncol, 6, pp.707~715 (2011)
- Han SW, "Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation", Clin Cancer Res, 12, pp.2538~2544 (2006)